European regulators have backed Tecvayli monotherapy after only one prior multiple myeloma treatment, potentially transforming Johnson & Johnson’s BCMA bispecific from a late-line therapy into a much larger second-line franchise.
Europe has approved teclistamab plus daratumumab after MajesTEC-3 showed an 83.4% reduction in progression or death and a significant overall-survival advantage versus established regimens.
Johnson & Johnson’s Tecvayli-Talvey regimen cut progression risk by 89% in MonumenTAL-6. See what the topline data still must prove.
FDA approves TECVAYLI plus DARZALEX FASPRO for relapsed multiple myeloma. Discover what the MajesTEC-3 data means for future immunotherapy strategies.
FDA approves J&J's teclistamab plus daratumumab for relapsed myeloma from second line. Analyse the MajesTEC-3 data, safety profile, and what this changes for treatment.
TECVAYLI outperformed standard regimens in relapsed/refractory myeloma. Find out what the Phase 3 MajesTEC-9 trial means for future treatment lines.
TECVAYLI and DARZALEX FASPRO show major survival benefits in second-line multiple myeloma. Find out what the MajesTEC-3 trial means for clinical practice.